<DOC>
	<DOC>NCT01771146</DOC>
	<brief_summary>A prospective evaluation of neoadjuvant FOLFIRINOX regimen in patients with non-metastatic pancreas cancer (Baylor University Medical Center and Texas Oncology Experience)</brief_summary>
	<brief_title>Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer</brief_title>
	<detailed_description>Patients with pancreas cancer will be enrolled and treated with a planned course of 6 cycles (3 months) of chemotherapy with FOLFIRINOX prior to undergoing surgical resection.</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>18 years of age or older Male or nonpregnant and nonlactating female Histologically or cytologically confirmed adenocarcinoma of pancreas Patients must have satisfactory blood counts and blood chemistry levels at baseline (refer to Appendix 2, Study Laboratory References Range). Patient has Eastern Cooperative Oncology Group(ECOG) Performance Status 0 to 1 (refer to Appendix 7): 0 Asymptomatic (Fully active, able to carry on all predisease activities without restriction) 1 Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work) Signed study consent form &lt;18 years of age Pregnant or lactating female Patient has islet cell neoplasms Patient has known brain metastases Patient has metastatic disease Active secondary malignancies Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy Known infection with hepatitis B, hepatitis C, or cirrhosis Major surgery or vascular device placement (excluding ports for IV medication/chemotherapy) within 2 weeks prior to Day 1 of treatment in study Prior chemotherapy or radiation for pancreatic cancer History of allergy or hypersensitivity to the study drugs Patient is enrolled in any outside (outside Baylor University Medical Center or Texas Oncology) clinical protocol or investigational trial Significant cardiac disease as defined as New York Heart Association (NYHA) classification III or IV, uncontrolled congestive heart failure (CHF), or prior myocardial infarction (MI) last 6months Any prior gastrointestinal (GI) disease or history of prior pelvic or abdominal radiation which in the opinion of the investigator may place the patient at increased risk Peripheral sensory neuropathy â‰¥ to grade 2 at baseline Significant comorbidities deemed by investigator as unsuitable for participation/enrollment Study consent form not signed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-metastatic Pancreas Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Cancer of Pancreas</keyword>
	<keyword>Adenocarcinoma of Pancreas</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>